Open-label extension study of etrasimod in moderately to severely active ulcerative colitis

Phase 3, open-label, single-arm trial of etrasimod in autoimmune colitis, sponsored by Arena Pharmaceuticals, Inc. Primary endpoints: Incidence of treatment-emergent adverse events and serious adverse events, Laboratory abnormalities and change from baseline in laboratory values and 1 more. Started Nov 2019; status: active, not recruiting.